comparemela.com

Latest Breaking News On - Biologic therapy in cancer - Page 1 : comparemela.com

Perioperative Nivolumab Improves EFS in Resectable NSCLC

Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy only.

United statesMarina garassinoBristol myers squibbTina casconeThoracic oncology programUniversity of chicagoEuropean society for medical oncologyEuropean societyMedical oncologyCancer medicineCancer centerNon small cell lung cancerLung cancerUng carcinomaAncer lungBiologic therapy in cancer

Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro

Six months of adjuvant nivolumab plus ipilimumab after nephrectomy for renal cell carcinoma offers no disease-free survival benefit, reveals trial that highlights treatment duration and tolerability.

New yorkUnited statesMemorial sloan kettering cancer centerFrance generalDominik bertholdRobertj motzerDrug administrationEuropean society for medical oncologyCentre hospitalier universitaire vaudoisEuropean societyMedical oncologyAnnual meetingNew york cityMedscape medical newsNew resultsMalignant kidney neoplasm

FDA Approves Neoadjuvant Nivolumab/Chemo for Early-Stage NSCLC

The pathologic complete response rate was 24% versus 2.2% with chemotherapy alone.

Mark awadDrug administrationDana farber cancer instituteBristol myers squibbLung cancerUng carcinomaAncer lungNon small cell lung cancerAlignant neoplasiaCombination chemotherapyBiologic therapy in cancerIological therapy in cancerIologics cancerBiologic therapyClinical researchClinical trials

Yescarta Label Updated: Prophylactic Steroids to Prevent CRS

However, labeling notes a potential increase in neurologic toxicity.

United statesFrank neumannB cell lymphomaAdverse effectsSide effectsChimeric antigen receptort cell therapyChimeric antigen receptorsHimeric immunoreceptorsHimerict cell receptorsRtificialt cell receptorsAr tBiologic therapyBiologic therapy in cancerIological therapy in cancerIologics cancerClinical research

ICIs for NSCLC: Patients With ILD Show Greater Risk

Immune checkpoint inhibitors can be effective in patients with non-small cell lung cancer and mild interstitial lung disease, but with a greater risk.

United statesYuan chengJarushka naidooKarthik sureshUniversity first hospitalJohns hopkins school of medicineSidney kimmel comprehensive cancer centerPeking university first hospitalMedscape medicalEast asianJohns hopkins schoolLung cancerUng carcinomaAncer lungInterstitial lung diseaseNon small cell lung cancer

vimarsana © 2020. All Rights Reserved.